California-based biopharmaceutical company plans to trade on the Nasdaq under the symbol ALMS.
Source: https://www.marketwatch.com/story/alumi ... topstories
Alumis readies $300 million IPO ahead of Phase 3 trial for plaque psoriasis drug
